肺癌血清p16基因启动子畸变甲基化检测

[目的]检测肺癌患者血清DNA中p16基因启动子畸变甲基化,并探讨其在肺癌早期诊断和预后评价中的作用。[方法]收集新鲜的肺癌组织及其对应的血清标本69例,肺良性疾病患者标本25例,健康人血清标本10例。采用PCR技术分别检测肿瘤组织DNA和血清游离DNA中p16基因启动子畸变甲基化的状况。[结果]28.99%(20/69)肺癌组织出现p16高甲基化;出现高甲基化的组织标本相对应的20例血清中有15例(75%)出现p16基因高甲基化。肺良性疾病患者及正常人的血清、DNA中均未见p16基因高甲基化。血清p16基因高甲基化与肺癌TNM分期及分化程度密切相关(P<0.01或P<0.05)。[结论]非小细胞肺癌血清中p16基因甲基化状况的检测,可能有助于非小细胞肺癌的早期诊断或预后评估。

Detection of Methylation in p16 Gene Promoter in Serum of Non-small Cell Lung Cancer

To detect methylation in p16gene promoter in serum of non-small cell lung can-cer(NSCLC),and to explore its significance for early diagnosis and prediciting prognosis in NSCLC.Sixty-nine tissue samples and their corresponding serum samples from patients with NSCLC,25serum samples from patients with lung benign diseases and10serum samples from healthy con-trol were collected for methylation mesurement by PCR technique.Methylated p16gene pro-moter was found in28.98%of NSCLC tissues(20of69)and in15/20serum samples no methylated p16gene promoter was found in serum samples with lung benign diseases and normal control.Methylated p16gene promoter in serum strongly correlated with TNM stage and differentiation in lung cancer(P<0.01or P<0.05).[Conclusion]The measurement of methylated p16gene promoter maybe helpful to early diagnosis and predicting prognosis for NSCLC.